New York, NY -- (SBWIRE) -- 01/16/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Earthlink Holdings Corp (NASDAQ:ELNK), Biodel Inc (NASDAQ:BIOD), Advanced Cell Technology, Inc (OTCMKTS:ACTC), Progenics Pharmaceuticals, Inc (NASDAQ:PGNX)
Earthlink Holdings Corp (NASDAQ:ELNK) showed a volume of 1.19 million shares by the end of last trade whereas the average volume of the stock remained 1.04 million shares. The stock opened the session at $5.05 but then moved to $4.93. At that price, the stock showed a negative performance of -1.79%. EarthLink Holdings Corp, formerly EarthLink, Inc., is a network, communications and information technology (IT) services provider to business and residential customers in the United States. The Company operates in two segments: Business Services and Consumer Services. EarthLink’s Business Services segment provides a range of data, voice, managed IT and equipment services to business customers.
Will ELNK Get Buyers Even After The Recent Rally? Find Out Here
Biodel Inc (NASDAQ:BIOD) opened the session at $3.01 and closed the session at $3.22. The stock showed a positive performance of 6.98% in previous trading session. Traded with volume of 1.18 million shares in the prior session and the average volume of the stock remained 804,063.00 shares. Biodel Inc. (Biodel) is a development-stage speciality biopharmaceutical company focused on the development and commercialization of treatments for diabetes. The Company develops its product candidates by applying its formulation technologies to existing drugs.
For How Long BIOD will fight for Profitability? Read This Trend Analysis report
Advanced Cell Technology, Inc (OTCMKTS:ACTC) opened the session at $0.06 and closed the session at $0.0607. The stock showed a positive performance of 0.50% in previous trading session. Traded with volume of 7.53 million shares in the prior session and the average volume of the stock remained 6.44 million shares. The beta of the stock remained -3.99. Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. The Company has acquired, developed and maintained a portfolio of patents and patent applications that forms the base for its research and development efforts in the area of embryonic and adult stem cell research.
Why Should Investors Buy ACTC After The Recent Gain? Just Go Here and Find Out
Progenics Pharmaceuticals, Inc (NASDAQ:PGNX) the stock decreased -1.03% and finished the session at $6.70. Traded with volume of 1.15 million shares in the prior session and the average volume of the stock remained 1.11 million shares. The beta of the stock remained 1.24. Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers.
Will PGNX Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)